SCHEMBL6627273

SCHEMBL6627273

COc1cccc(C(=O)N[C@H]2CCC(=O)N3CCC[C@@H](C(=O)N[C@H](C(=O)CSc4nc5ccccc5s4)C(C)C)N3C2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 8/20 0.46
IL1B P01584 2/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
LCK P06239 5/20 0.39
UBE2M P61081 1/20 0.39
DCUN1D1 Q96GG9 1/20 0.39
THRB P10828 1/20 0.39
GZMB P10144 1/20 0.38
CASP3 P42574 1/20 0.38
CASP8 Q14790 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6631474 1.00 CASP1 (0.46) CASP1IL1BMAPTLMNATP53
SCHEMBL6631476 0.87 CASP1 (0.48) CASP1IL1BLMNATP53LCK
SCHEMBL6626382 0.85 CASP1 (0.44) CASP1IL1BMAPTLMNALCK
SCHEMBL6627597 0.85 CASP1 (0.44) CASP1IL1BMAPTLMNALCK
SCHEMBL7086596 0.85 CASP1 (0.43) CASP1IL1BMAPTLMNALCK
SCHEMBL6629019 0.85 CASP1 (0.43) CASP1IL1BMAPTLMNALCK
SCHEMBL6627592 0.85 CASP1 (0.41) CASP1IL1BLCK
SCHEMBL6627596 0.85 CASP1 (0.41) CASP1IL1BLCK
SCHEMBL6628216 0.81 CASP1 (0.40) CASP1IL1BMAPTLMNALCK
SCHEMBL6628214 0.81 CASP1 (0.40) CASP1IL1BMAPTLMNALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1246824-B1 CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AVENTIS PHARMA SA (FR) 2004-06-09 EP claimed
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof AVENTIS PHARMA S.A. (FR) 2003-05-29 US claimed
EP-1246824-B1 CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AVENTIS PHARMA SA (FR) 2004-06-09 EP disclosed
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof AVENTIS PHARMA S.A. (FR) 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof HRH4, HRH3, HRH2 CASP1 2506/4885IL1B 2994/4885MAPT 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.